2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Hao G. Nguyen MD, PhD, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.
Hao G. Nguyen MD, PhD, associate professor in residence, Urologic Oncology, Richard and Leilani Grinold Endowed professorship in Urology Education, University of California San Francisco, discusses the efficacy and safety of IS-002, a prostate-specific membrane antigen (PSMA)–targeting fluorophore, for image-guided surgery in patients with prostate cancer undergoing robotic prostatectomy.
A phase 1 trial (NCT04574401) investigated the efficacy and safety of IS-022 for fluorescent identification and delineation of the positive cancer margins and metastatic lymph nodes during prostatectomy. Findings from the trial were presented at the 2022 American Urological Association Annual Meeting.
Discoloration of urine and feces was the only notable adverse effect observed with the use of IS-002, Nguyen says. In terms of efficacy, and local and regional disease was identified in 6 of 24 evaluable patients, Nguyen explains. Notably, lymph node metastases that were not visible on a conventional white light endoscopy were found in 3 patients, Nguyen adds.
Disease in the resection bed was found in 5 patients, which was also not visible on white light endoscopy, Nguyen continues. Further evaluation of IS-022 will take place in a phase 2 multi-institutional trial with a larger cohort of patients, and planning for that study is underway, Nguyen concludes.